Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Fox Chase Cancer Center: Clinical Trials & FDA Approval Profile

Fox Chase Cancer Center (Global / Institutional) sponsors 26 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 17 active protocols (9 recruiting now), 0 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)34.6%
Median Closed Enrollment vs National (145 pts)37 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Fox Chase Cancer Center
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)26
Active Pipeline (Recruiting Now)17 (9)
Completed vs Stopped Early0 / 9 (34.6%)
Median Closed Actual Enrollment37 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Fox Chase Cancer Center
Hospital Research SiteLocationShared Protocols
Fox Chase Cancer CenterPhiladelphia, PA18

Explore interactive annual charts and M&A subsidiary rollups in the Fox Chase Cancer Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI